Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
SAN DIEGO, Jan. 02, 2018 -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph.D., founder and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 11:30 a.m. PT. The conference is being held at the Westin St. Francis Hotel in San Francisco.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage biotechnology company focusing on treatments for rare endocrine disorders and endocrine-related cancers. The company is currently conducting a Phase 1 trial with its oral somatostatin agonist, CRN00808, for the treatment of acromegaly, an orphan disease affecting more than 24,000 people in the United States. The company is also developing other oral somatostatin agonists for neuroendocrine tumors, hyperinsulinism and chronic pain, as well as an oral small molecule for Cushing's disease. Crinetics was founded by a team of scientists with a proven track record of endocrine drug discovery and development. The company is backed by top life sciences investors including 5AM Ventures, Versant Ventures and Vivo Capital, and is headquartered in San Diego. For additional information please visit www.crinetics.com.
Contacts:
R. Scott Struthers, Ph.D.
Founder & CEO
[email protected]
(858) 450-6464
Robert H. Uhl
Westwicke Partners
[email protected]
(858) 356-5932
